Culture Development Featured Articles

  1. SurModics And Donaldson Company Announce Introduction Of The First Jointly Developed Nanofiber Cell Culture Product 1/31/2006
    SurModics, Inc., a provider of surface modification and drug delivery technologies to the healthcare industry, and Donaldson Company, Inc., a manufacturer of filtration systems, announced today the introduction of jointly developed Ultra-Web Synthetic ECM (extracellular matrix) surfaces for cell culture as a research product
  2. BioCrystal, Ltd. Commercializes Novel Cell Culture Technology 1/30/2006
    BioCrystal's OptiCell is fully developed - Manufacturing processes and associated production quality standards are in place - Third party collaborations have successfully demonstrated the versatility of OptiCell for use in a broad range of applications for which traditional disposable cell culture devices are not suited
  3. Celliance™ Introducing Serum-Free Hybri-Cyte™ To Portfolio Of Cell Culture Products 2/15/2005
    Serologicals Corporation (NASDAQ: SERO) announced today that Celliance Corporation, its wholly-owned subsidiary, is announcing the introduction of Hybri-CYTE™, a serum-free cell culture supplement designed and optimized for use in hybridoma cell culture that has been proven to work with mouse, rat and rabbit derived cell-lines...
  4. CLONTECH and 3M combine expertise with the new CLONdisc E. coli Culture Medium System 12/10/2000
    CLONTECH is introducing the CLONdisc E. coli Culture Medium System, the new paradigm in plating that may make agar plates obsolete
  5. Liver Culture for HBV Virus Developed by Amphioxus 4/12/2000
    Amphioxus Cell Technologies has produced a human liver cell culture system that permits infection and replication of the human hepatitis B virus (HBV)...
  6. Analytical QbD at Teva: Knowledge Is Power Only When You Share It

    Rosario LoBrutto, is currently Senior Director, Head of Development Parenterals at Teva. Throughout his career he has designed, coordinated, and implemented QbD programs and provided risk management trainings to product development units (quality, analytical, formulation, process chemists), and quality control, regulatory, and operations units. He understands the value of risk assessment and strategy for proactive failure reduction as opposed to reactive trouble shooting. In his interpretation of the ICH Harmonised Tripartite Guideline for Pharmaceutical Development Q9, a guidance document for QbD, LoBrutto breaks the QbD process down into three phases of risk facilitation as it relates to analytics.